

MAIL STOP AMENDMENT

Serial No. 10/590,803


Page 2 of 47

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Previously presented) A compound of formula I,



in which

R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy,

R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy,

or in which

R1 and R2 together are a 1-2C-alkylenedioxy group,

R3 is hydrogen or 1-4C-alkyl,

R31 is hydrogen or 1-4C-alkyl,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 3 of 47

either, in a first embodiment (embodiment a),

R4 is -O-R41, in which

R41 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, hydroxy-2-4C-alkyl, 1-7C-alkylcarbonyl, or completely or predominantly fluorine-substituted 1-4C-alkyl, and

R5 is hydrogen or 1-4C-alkyl,

or, in a second embodiment (embodiment b),

R4 is hydrogen or 1-4C-alkyl, and

R5 is -O-R51, in which

R51 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, hydroxy-2-4C-alkyl, 1-7C-alkylcarbonyl, or completely or predominantly fluorine-substituted 1-4C-alkyl,

Har is optionally substituted by R6 and/or R7 and/or R8, and is a 5- to 10-membered monocyclic or fused bicyclic unsaturated or partially saturated heteroaryl radical comprising 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur, in which

R6 is halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, 1-4C-alkylthio, sulfanyl, cyano, 1-4C-alkoxycarbonyl, carboxyl, hydroxyl, oxo, -A-N(R61)R62, pyridyl, or completely or partially fluorine-substituted 1-4C-alkyl, in which

A is a bond or 1-4C-alkylene,

R61 is hydrogen or 1-4C-alkyl,

R62 is hydrogen or 1-4C-alkyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are

attached, form a heterocyclic ring Het1, in which

Het1 is optionally substituted by R611, and is a 3- to 7-membered saturated or unsaturated monocyclic heterocyclic ring radical comprising the nitrogen atom, to which R61 and R62 are bonded, and optionally one to three further heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur, in which

R611 is 1-4C-alkyl,

R7 is 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, 1-4C-alkylthio, sulfanyl, hydroxyl, oxo, amino or mono- or di-1-4C-alkylamino,

R8 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

2. (Previously presented) A compound of formula I according to claim 1 in which

R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy,

R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy,

or in which

R1 and R2 together are a 1-2C-alkylenedioxy group,

R3 is hydrogen or 1-4C-alkyl,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 5 of 47

R31 is hydrogen or 1-4C-alkyl,

either, in a first embodiment (embodiment a),

R4 is -O-R41, in which

R41 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, hydroxy-2-4C-alkyl, 1-7C-alkylcarbonyl, or completely or predominantly fluorine-substituted 1-4C-alkyl, and

R5 is hydrogen or 1-4C-alkyl,

or, in a second embodiment (embodiment b),

R4 is hydrogen or 1-4C-alkyl, and

R5 is -O-R51, in which

R51 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, hydroxy-2-4C-alkyl, 1-7C-alkylcarbonyl, or completely or predominantly fluorine-substituted 1-4C-alkyl,

Har is optionally substituted by R6 and/or R7 and/or R8, and is a 5- to 10-membered monocyclic or fused bicyclic unsaturated or partially saturated heteroaryl radical comprising 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur, in which

R6 is halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, 1-4C-alkylthio, cyano, 1-4C-alkoxycarbonyl, carboxyl, hydroxyl, -A-N(R61)R62, pyridyl, or completely or partially fluorine-substituted 1-4C-alkyl, in which

A is a bond or 1-4C-alkylene,

R61 is hydrogen or 1-4C-alkyl,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 6 of 47

R62 is hydrogen or 1-4C-alkyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

Het1 is optionally substituted by R611, and is a 3- to 7-membered saturated or unsaturated monocyclic heterocyclic ring radical comprising the nitrogen atom, to which R61 and R62 are bonded, and optionally one to three further heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur, in which

R611 is 1-4C-alkyl,

R7 is 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, 1-4C-alkylthio, hydroxyl, amino or mono- or di-1-4C-alkylamino,

R8 is halogen,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

3. (Previously presented) A compound of formula I according to claim 1 in which

R1 is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R2 is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R3 is hydrogen,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 7 of 47

R31 is hydrogen,

either, in a first embodiment (embodiment a),

R4 is -O-R41, in which

R41 is hydrogen or 1-4C-alkylcarbonyl, and

R5 is hydrogen,

or, in a second embodiment (embodiment b),

R4 is hydrogen, and

R5 is -O-R51, in which

R51 is hydrogen or 1-4C-alkylcarbonyl,

wherein in one embodimental detail,

Har is optionally substituted by R6 and/or R7, and is a 9- or 10-membered fused bicyclic partially saturated heteroaryl radical comprising a heteroatom-free benzene ring and, in the other ring, 1 or 2 heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur,

whereby said Har ring system is attached to the parent molecular group via any substitutable carbon atom of the benzene ring,

in which

R6 is 1-4C-alkyl or halogen,

R7 is halogen,

or, in another embodimental detail,

Har is Cyc2, in which

Cyc2 is optionally substituted by R6 and/or R7 and/or R8, and is a 9- or 10-membered

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 8 of 47

fused bicyclic fully aromatic ring system containing one to four heteroatoms each of which is selected from the group consisting of nitrogen, oxygen and sulphur, and which Cyc2 ring system is made up of a first constituent (constituent m) being a benzene or pyridine ring,

and fused to said first constituent m,

a second constituent (constituent n) being a 5- or 6-membered monocyclic heteroaryl ring comprising one to three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulphur,

whereby said Cyc2 ring system is attached to the parent molecular group via any substitutable ring carbon atom of the constituent m,

in which

R6 is 1-4C-alkyl or 1-4C-alkoxy,

R7 is 1-4C-alkoxy,

R8 is 1-4C-alkyl,

or, in yet another embodiment detail,

either

Har is optionally substituted by R6 and/or R7 and/or R8, and is a 6-membered monocyclic unsaturated heteroaryl radical comprising one or two nitrogen atoms,

or

Har is optionally substituted by R6 and/or R7, and is a 5-membered monocyclic unsaturated heteroaryl radical comprising one to four heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulphur,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 9 of 47

in which

R6 is halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, 1-4C-alkylthio, sulfanyl, cyano, 1-4C-alkoxycarbonyl, carboxyl, hydroxyl, oxo, -A-N(R61)R62, or pyridyl, in which

A is a bond or 1-4C-alkylene,

R61 is hydrogen or 1-4C-alkyl,

R62 is hydrogen or 1-4C-alkyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

either, in one facet,

Het1 is optionally substituted by R611 on a ring nitrogen atom, and is a 5- to 7-membered saturated monocyclic heterocyclic ring radical comprising the nitrogen atom, to which R61 and R62 are bonded, and optionally one further heteroatom selected from the group consisting of oxygen, nitrogen and sulfur, in which

R611 is 1-4C-alkyl,

or, in another facet,

Het1 is a 5-membered unsaturated monocyclic heteroaryl radical comprising the nitrogen atom, to which R61 and R62 are bonded, and optionally one to three further nitrogen atoms,

R7 is 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, 1-4C-alkylthio, sulfanyl, hydroxyl, oxo, amino, or mono- or di-1-4C-alkylamino,

R8 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

4. (Previously presented) A compound of formula I according to claim 1 in which
- R1 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,
- R2 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,
- R3 is hydrogen,
- R31 is hydrogen,
- either, in a first embodiment (embodiment a),
- R4 is -O-R41, in which
- R41 is hydrogen or 1-4C-alkylcarbonyl, and
- R5 is hydrogen,
- or, in a second embodiment (embodiment b),
- R4 is hydrogen, and
- R5 is -O-R51, in which
- R51 is hydrogen or 1-4C-alkylcarbonyl,
- wherein in one embodimental detail,
- Har is Cyc1, in which
- Cyc1 is optionally substituted by halogen on its benzene ring, and is indolinyI, isoindolinyI, tetrahydroquinolinyI, tetrahydroisoquinolinyI, 3,4-

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 11 of 47

dihydrobenzo[1,4]oxazinyl, 1-methyl-indolinyl, 2-methyl-isoindolinyl, 1-methyl-tetrahydroquinolinyl, 2-methyl-tetrahydroisoquinolinyl, 4-methyl-3,4-dihydrobenzo[1,4]oxazinyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothiophenyl, benzo[1,3]dioxolyl, dihydrobenzo[1,4]dioxinyl, chromanyl, chromenyl, or 2,2-difluoro-benzo[1,3]dioxolyl,

whereby said Cyc1 ring system is attached to the parent molecular group via any substitutable carbon atom of the benzene ring,

or, in another embodiment detail,

Har is Cyc2, in which

Cyc2 is optionally substituted by R6 and/or R7 and/or R8, and is a 9- or 10-membered fused bicyclic fully aromatic ring system containing one to three heteroatoms each of which is selected from the group consisting of nitrogen, oxygen and sulphur, and which Cyc2 ring system is made up of

a first constituent (constituent m) being a benzene or pyridine ring,

and fused to said first constituent m,

a second constituent (constituent n) being a 5- or 6-membered monocyclic heteroaryl ring comprising one to three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulphur,

whereby said Cyc2 ring system is attached to the parent molecular group via any substitutable ring carbon atom of the constituent m,

in which

R6 is 1-4C-alkyl or 1-4C-alkoxy,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 12 of 47

R7 is 1-4C-alkoxy,

R8 is 1-4C-alkyl,

or, in yet another embodiment detail,

Har is optionally substituted by R6 and/or R7 and/or R8, and is a pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl radical, in which

R6 is halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylthio, 1-4C-alkoxycarbonyl, carboxyl, hydroxyl, oxo, or -A-N(R61)R62, in which

A is a bond or 1-4C-alkylene,

R61 is 1-4C-alkyl,

R62 is 1-4C-alkyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

either

Het1 is piperidin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl or 4N-methyl-piperazin-1-yl,

or

Het1 is pyrrol-1-yl, pyrazol-1-yl, triazol-1-yl or imidazol-1-yl,

R7 is 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylthio, hydroxyl, oxo, or di-1-4C-alkylamino,

R8 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

or, in still yet another embodiment detail,

Har is optionally substituted by R6 and/or R7, and is a 5-membered monocyclic unsaturated heteroaryl radical comprising one to four heteroatoms independently

selected from the group consisting of oxygen, nitrogen and sulphur,

in which

R6 is 1-4C-alkyl, or pyridyl,

R7 is 1-4C-alkyl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

5. (Previously presented) A compound of formula I according to claim 1 in which one of R1 and R2 is methoxy or ethoxy, and the other is methoxy, ethoxy, 2,2-difluoroethoxy or difluoromethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen or 1-4C-alkylcarbonyl, and

R5 is hydrogen,

in one embodimental detail,

Har is Cyc1, in which

Cyc1 is optionally substituted by chlorine on its benzene ring, and is indoliny, isoindoliny, tetrahydroquinoliny, tetrahydroisoquinoliny, or 3,4-dihydrobenzo[1,4]oxazinyl, 1-methyl-indoliny, 2-methyl-isoindoliny, 1-methyl-tetrahydroquinoliny, 2-methyl-tetrahydroisoquinoliny, or 4-methyl-3,4-dihydrobenzo[1,4]oxazinyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothiophenyl, benzo[1,3]dioxolyl, dihydrobenzo[1,4]dioxinyl,

chromanyl, chromenyl, or 2,2-difluoro-benzo[1,3]dioxolyl,

whereby said Cyc1 ring system is attached to the parent molecular group via any substitutable carbon atom of the benzene ring,

or, in another embodiment detail,

Har is Cyc2, in which

Cyc2 is optionally substituted by R6 and/or R7, and is

either

pyrazolopyridinyl or 1-methyl-pyrazolopyridinyl,

whereby these radicals may be attached to the parent molecular group via the pyridine ring,

or

benzothiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, 1-methyl-benzimidazolyl, 1-methyl-indazolyl, benzoxadiazolyl, benzotriazolyl, 1H-methyl-benzotriazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl or cinnolinyl,

whereby these radicals may be attached to the parent molecular group via the benzene ring,

in which

R6 is 1-4C-alkyl or 1-4C-alkoxy,

R7 is 1-4C-alkoxy,

or, in yet another embodiment detail,

Har is optionally substituted by R6 and/or R7 and/or R8, and is a pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl radical, in which

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 15 of 47

R6 is halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylthio, 1-4C-alkoxycarbonyl, carboxyl, hydroxyl, oxo, or -A-N(R61)R62, in which

A is a bond or 1-4C-alkylene,

R61 is 1-4C-alkyl,

R62 is 1-4C-alkyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

either

Het1 is piperidin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl or 4N-methyl-piperazin-1-yl,

or

Het1 is pyrrol-1-yl, pyrazol-1-yl, triazol-1-yl or imidazol-1-yl,

R7 is 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylthio, hydroxyl, oxo, or di-1-4C-alkylamino,

R8 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

or, in still yet another embodiment detail,

Har is optionally substituted by R6 and/or R7, and is a 5-membered monocyclic unsaturated heteroaryl radical comprising one to four heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulphur,

in which

R6 is 1-4C-alkyl, or pyridyl,

R7 is 1-4C-alkyl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 16 of 47

6. (Previously presented) A compound of formula I according to claim 1 in which

R1 is methoxy or ethoxy,

R2 is methoxy, ethoxy, 2,2-difluoroethoxy or difluoromethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen or acetyl, and

R5 is hydrogen,

in one embodimental detail,

Har is Cyc1, in which

Cyc1 is benzo[1,3]dioxol-5-yl, dihydrobenzo[1,4]dioxin-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, or 5-chloro-4-methyl-3,4-dihydrobenzo[1,4]oxazin-7-yl,

or, in another embodimental detail,

Har is Cyc2, in which

Cyc2 is quinolin-6-yl, benzofurazan-5-yl, benzothiazol-6-yl, 1-methyl-1H-benzotriazol-5-yl or 4-methoxy-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-yl, benzo[1,2,3]thiadiazol-5-yl or quinoxalin-5-yl,

or, in yet another embodimental detail,

Har is optionally substituted by R6 and/or R7 and/or R8, and is a pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl radical, in which

R6 is chlorine, methyl, methoxy, ethoxy, methylthio, methoxycarbonyl, carboxyl, hydroxyl, oxo, or -A-N(R61)R62, in which

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 17 of 47

A is a bond or ethylene,

R61 is methyl,

R62 is methyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

either

Het1 is piperidin-1-yl, pyrrolidin-1-yl or morpholin-4-yl,

or

Het1 is pyrazol-1-yl or imidazol-1-yl,

R7 is methyl, methoxy, ethoxy, methylthio or dimethylamino,

R8 is chlorine or methoxy,

or, in still yet another embodiment detail,

Har is isoxazolyl, 1-methylimidazolyl, or pyridyl-thiazolyl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

7. (Previously presented) A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, 2,2-difluoroethoxy or difluoromethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen or acetyl, and

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 18 of 47

R5 is hydrogen,

in one embodiment detail,

Har is Cyc1, in which

Cyc1 is benzo[1,3]dioxol-5-yl, dihydrobenzo[1,4]dioxin-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, or 5-chloro-4-methyl-3,4-dihydrobenzo[1,4]oxazin-7-yl,

or, in another embodiment detail,

Har is Cyc2, in which

Cyc2 is quinolin-6-yl, benzofurazan-5-yl, benzothiazol-6-yl, 1-methyl-1H-benzotriazol-5-yl or 4-methoxy-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-yl, benzo[1,2,3]

thiadiazol-5-yl or quinoxalin-5-yl,

or, in yet another embodiment detail,

Har is pyridin-3-yl, pyridin-4-yl, 6-(morpholin-4-yl)-pyridin-3-yl, 6-(piperidin-1-yl)-pyridin-3-yl, 6-(pyrazol-1-yl)-pyridin-3-yl, 6-(imidazol-1-yl)-pyridin-3-yl, 6-methoxycarbonyl-pyridin-3-yl, 3-methoxycarbonyl-pyridin-2-yl, 2-methoxy-pyridin-3-yl, 6-methoxy-pyridin-3-yl, 2-methylsulfanyl-pyridin-3-yl, 6-hydroxy-pyridin-3-yl, 6-carboxy-pyridin-3-yl, pyrimidin-5-yl, 2-methoxy-pyrimidin-5-yl, 2-dimethylamino-pyrimidin-5-yl, 2-methylsulfanyl-pyrimidin-5-yl, pyrazin-2-yl, 5-methyl-pyrazin-2-yl, 6-[2-(pyrrolidin-1-yl)-ethyl]-pyridin-3-yl, 2,6-dimethoxy-pyridin-3-yl, 2,6-dimethoxy-pyridin-4-yl, 4,6-dimethoxy-pyridin-3-yl, 5,6-dimethoxy-pyridin-3-yl, 4,6-diethoxy-pyridin-3-yl, 5-ethoxy-6-methoxy-pyridin-3-yl, 1-methyl-1H-pyridin-2-one-5-yl, 2,6-dimethoxy-pyrimidin-4-yl, 2,4-dimethoxy-pyrimidin-5-yl, 4,6-dimethoxy-pyrimidin-5-yl, 4-methyl-2-methylsulfanyl-pyrimidin-5-yl, 5-chloro-2-methylsulfanyl-

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 19 of 47

pyrimidin-4-yl, 4-chloro-2-dimethylamino-pyrimidin-5-yl, 2-dimethylamino-4-methoxy-pyrimidin-5-yl, 1-methyl-1H-pyrimidin-2-one-5-yl, 3,6-dimethoxy-pyridazin-4-yl, 4-chloro-2,6-dimethoxy-pyridin-3-yl, 3-chloro-2,6-dimethoxy-pyridin-4-yl, 5-chloro-2,6-bisdimethylamino-pyrimidin-4-yl, or 2,4,6-trimethoxy-pyrimidin-5-yl,

or, in still yet another embodiment detail,

Har is isoxazol-5-yl, 1-methylimidazol-2-yl, 1-methylimidazol-5-yl, or 2-(pyridin-3-yl)-thiazol-4-yl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

8. (Previously presented) A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is ethoxy, 2,2-difluoroethoxy or difluoromethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen, and

R5 is hydrogen,

in one embodiment detail,

Har is Cyc1, in which

Cyc1 is benzo[1,3]dioxol-5-yl, dihydrobenzo[1,4]dioxin-5-yl, 2,2-difluorobenzo[1,3]dioxol-5-yl, or 5-chloro-4-methyl-3,4-dihydrobenzo[1,4]oxazin-7-yl,

or, in another embodiment detail,

Har is Cyc2, in which

Cyc2 is quinolin-6-yl, benzofurazan-5-yl, benzothiazol-6-yl, 1-methyl-1H-benzotriazol-5-yl or 4-methoxy-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-yl, benzo[1,2,3]thiadiazol-5-yl or quinoxalin-5-yl,

or, in yet another embodiment detail,

Har is pyridin-3-yl, pyridin-4-yl, 6-(morpholin-4-yl)-pyridin-3-yl, 6-(piperidin-1-yl)-pyridin-3-yl, 6-(pyrazol-1-yl)-pyridin-3-yl, 6-(imidazol-1-yl)-pyridin-3-yl, 6-methoxycarbonyl-pyridin-3-yl, 3-methoxycarbonyl-pyridin-2-yl, 2-methoxy-pyridin-3-yl, 6-methoxy-pyridin-3-yl, 2-methylsulfanyl-pyridin-3-yl, 6-hydroxy-pyridin-3-yl, 6-carboxy-pyridin-3-yl, pyrimidin-5-yl, 2-methoxy-pyrimidin-5-yl, 2-dimethylamino-pyrimidin-5-yl, 2-methylsulfanyl-pyrimidin-5-yl, pyrazin-2-yl, 5-methyl-pyrazin-2-yl, 6-[2-(pyrrolidin-1-yl)-ethyl]-pyridin-3-yl, 2,6-dimethoxy-pyridin-3-yl, 2,6-dimethoxy-pyridin-4-yl, 4,6-dimethoxy-pyridin-3-yl, 5,6-dimethoxy-pyridin-3-yl, 4,6-diethoxy-pyridin-3-yl, 5-ethoxy-6-methoxy-pyridin-3-yl, 1-methyl-1H-pyridin-2-one-5-yl, 2,6-dimethoxy-pyrimidin-4-yl, 2,4-dimethoxy-pyrimidin-5-yl, 4,6-dimethoxy-pyrimidin-5-yl, 4-methyl-2-methylsulfanyl-pyrimidin-5-yl, 5-chloro-2-methylsulfanyl-pyrimidin-4-yl, 4-chloro-2-dimethylamino-pyrimidin-5-yl, 2-dimethylamino-4-methoxy-pyrimidin-5-yl, 1-methyl-1H-pyrimidin-2-one-5-yl, 3,6-dimethoxy-pyridazin-4-yl, 4-chloro-2,6-dimethoxy-pyridin-3-yl, 3-chloro-2,6-dimethoxy-pyridin-4-yl, 5-chloro-2,6-bisdimethylamino-pyrimidin-4-yl, or 2,4,6-trimethoxy-pyrimidin-5-yl,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 21 of 47

or, in still yet another embodiment detail,

Har is isoxazol-5-yl, 1-methylimidazol-2-yl, 1-methylimidazol-5-yl, or 2-(pyridin-3-yl)-thiazol-4-yl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

9. (Currently amended) A compound of formula I according to claim 1 in which

R1 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R2 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

in one embodiment detail (detail 1),

Har is optionally substituted by R6 and/or R7, and is benzo[1,4]dioxanyl or benzo[1,3]dioxolyl, in which

R6 is fluorine,

R7 is fluorine,

or, in another embodiment detail (detail 2),

Har is quinolinyl, benzofurazanyl or benzothiazolyl,

or, in yet another embodiment detail (detail 3),

either

Har is optionally substituted by R6 and/or R7, and is pyridinyl, in which

R6 is 1-4C-alkoxy, -A-N(R61)R62, in which

A is a bond,

R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

Het1 is morpholinyl, thiomorpholinyl, N-(R611)-piperazinyl or 4-N-(R611)-homopiperazinyl, in which

R611 is 1-2C-alkyl,

R7 is 1-4C-alkoxy,

or

Har is optionally substituted by R6, and is isoxazolyl, imidazolyl or thiazolyl, in which

R6 is 1-4C-alkyl or pyridyl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

10. (Previously presented) A compound of formula I according to claim 1 in which

R1 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R2 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 23 of 47

R3 is hydrogen,

R31 is hydrogen, R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

in one embodiment detail,

Har is Cyc1, in which

Cyc1 is dihydrobenzo[1,4]dioxinyl, benzo[1,3]dioxolyl or 2,2-difluoro-benzo[1,3]dioxolyl,
or, in another embodiment detail,

Har is Cyc2, in which

either

Cyc2 is quinolinyl, benzofurazanyl or benzothiazolyl,

or

Cyc2 is 1-(1-4C-alkyl)-1H-benzotriazolyl or 1-(1-4C-alkyl)-4-methoxy-3-methyl-1H-pyrazolo[3,4-b]pyridinyl,

or, in yet another embodiment detail,

either

Har is pyridinyl, pyrimidinyl, isoxazolyl, 1-(1-4C-alkyl)-1H-imidazolyl, methyl-pyrazinyl or pyridyl-thiazolyl,

or

Har is substituted by R6 and/or R7 and/or R8, and is pyrimidinyl, in which

R6 is 1-4C-alkoxy,

R7 is 1-4C-alkoxy,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 24 of 47

R8 is 1-4C-alkoxy,

or

Har is substituted by R6, and is pyridinyl, in which

R6 is 1-4C-alkoxycarbonyl,

or

Har is substituted by R6, and is pyridinyl, in which

R6 is morpholin-4-yl, piperidin-1-yl, pyrazol-1-yl or imidazol-1-yl,

or

Har is substituted by R6 and/or R7, and is pyridinyl, in which

R6 is 1-4C-alkoxy,

R7 is 1-4C-alkoxy,

or

Har is substituted by R6 and R7 and R8, and is pyridinyl, in which

R6 is 1-4C-alkoxy,

R7 is 1-4C-alkoxy,

R8 is chlorine,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 25 of 47

11. (Previously presented) A compound of formula I according to claim 1 in which
- R1 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,
- R2 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,
- R3 is hydrogen,
- R31 is hydrogen,
- R4 is -O-R41, in which
- R41 is hydrogen or 1-4C-alkylcarbonyl,
- R5 is hydrogen,
- Har is optionally substituted by R6 and/or R7 and/or R8, and is a pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl radical, in which
- R6 is halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylthio, 1-4C-alkoxycarbonyl, carboxyl, hydroxyl, oxo, or -A-N(R61)R62, in which
- A is a bond or 1-4C-alkylene,
- R61 is 1-4C-alkyl,
- R62 is 1-4C-alkyl,
- or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which
- either
- Het1 is piperidin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl or 4N-methyl-piperazin-1-yl,

or

Het1 is pyrrol-1-yl, pyrazol-1-yl, triazol-1-yl or imidazol-1-yl,

R7 is 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylthio, hydroxyl, oxo, or di-1-4C-alkylamino,

R8 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

12. (Previously presented) A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

Har is substituted by R6, and is pyridinyl, in which

R6 is methoxy, ethoxy, methylthio, methoxycarbonyl, hydroxyl, carboxyl, or -A-N(R61)R62, in which

A is a bond, or ethylene,

R61 is methyl,

R62 is methyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

either

Het1 is piperidin-1-yl, pyrrolidin-1-yl or morpholin-4-yl,

or

Het1 is pyrazol-1-yl or imidazol-1-yl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

13. (Previously presented) A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

Har is 6-(morpholin-4-yl)-pyridin-3-yl, 6-(piperidin-1-yl)-pyridin-3-yl, 6-(pyrazol-1-yl)-pyridin-3-yl, 6-(imidazol-1-yl)-pyridin-3-yl, 6-methoxycarbonyl-pyridin-3-yl, 3-methoxycarbonyl-pyridin-2-yl,

2-methoxy-pyridin-3-yl, 6-methoxy-pyridin-3-yl, 2-methylsulfanyl-pyridin-3-yl, 6-hydroxy-pyridin-3-yl, 6-carboxy-pyridin-3-yl, 2-methoxy-pyrimidin-5-yl, 2-dimethylamino-pyrimidin-5-yl, 2-methylsulfanyl-pyrimidin-5-yl, 5-methyl-pyrazin-2-yl, or 6-[2-(pyrrolidin-1-yl)-ethyl]-pyridin-3yl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 28 of 47

14. (Previously presented) A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

either

Har is substituted by R6 and R7, and is a pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl radical, in which

R6 is methoxy or ethoxy, and

R7 is methoxy or ethoxy,

or

R6 is oxo, and

R7 is methyl,

or

R6 is methylthio, and

R7 is methyl,

or

R6 is chlorine, and

R7 is methylthio,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 29 of 47

or

R6 is dimethylamino, and

R7 is methoxy or ethoxy,

or

R6 is dimethylamino, and

R7 is dimethylamino,

or

Har is substituted by R6 and R8, and is a pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl radical, in which

R6 is dimethylamino, and

R8 is chlorine,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

15. (Previously presented) A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

Har is substituted by R6 and R7, and is pyridinyl, in which

either

R6 is methoxy or ethoxy, and

R7 is methoxy or ethoxy,

or

R6 is oxo, and

R7 is methyl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

16. (Previously presented) A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

either

Har is substituted by R6 and R7, and is pyrimidinyl, in which

R6 is methoxy or ethoxy, and

R7 is methoxy or ethoxy,

or

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 31 of 47

R6 is oxo, and

R7 is methyl,

or

R6 is methylthio, and

R7 is methyl,

or

R6 is chlorine, and

R7 is methylthio,

or

R6 is dimethylamino, and

R7 is methoxy or ethoxy,

or

Har is substituted by R6 and R8, and is pyrimidinyl, in which

R6 is dimethylamino, and

R8 is chlorine,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

17. (Previously presented) A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 32 of 47

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

Har is substituted by R6 and R7, and is pyridazinyl, in which

R6 is methoxy or ethoxy, and

R7 is methoxy or ethoxy,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

18. (Previously presented) A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

Har is 2,6-dimethoxy-pyridin-3-yl, 2,6-dimethoxy-pyridin-4-yl, 4,6-dimethoxy-pyridin-3-yl, 5,6-dimethoxy-pyridin-3-yl, 4,6-diethoxy-pyridin-3-yl, 5-ethoxy-6-methoxy-pyridin-3-yl, 1-methyl-1H-pyridin-2-one-5-yl, 2,6-dimethoxy-pyrimidin-4-yl, 2,4-dimethoxy-pyrimidin-5-yl, 4,6-dimethoxy-pyrimidin-5-yl, 4-methyl-2-methylsulfanyl-pyrimidin-5-yl, 5-chloro-2-methylsulfanyl-pyrimidin-4-yl, 4-chloro-

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 33 of 47

2-dimethylamino-pyrimidin-5-yl, 2-dimethylamino-4-methoxy-pyrimidin-5-yl, 1-methyl-1H-pyrimidin-2-one-5-yl, or 3,6-dimethoxy-pyridazin-4-yl,
or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

19. (Previously presented) A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

Har is any one selected from the group consisting of

6-(imidazol-1-yl)-pyridin-3-yl, pyrimidin-5-yl, 2-methoxy-pyrimidin-5-yl, 2-dimethylamino-pyrimidin-5-yl, 2-methylsulfanyl-pyrimidin-5-yl, 2,6-dimethoxy-pyridin-3-yl, 2,6-dimethoxy-pyridin-4-yl, 4,6-dimethoxy-pyridin-3-yl, 5,6-dimethoxy-pyridin-3-yl, 4,6-diethoxy-pyridin-3-yl, 5-ethoxy-6-methoxy-pyridin-3-yl, 1-methyl-1H-pyridin-2-one-5-yl, 2,6-dimethoxy-pyrimidin-4-yl, 2,4-dimethoxy-pyrimidin-5-yl, 4,6-dimethoxy-pyrimidin-5-yl, 2-dimethylamino-4-methoxy-pyrimidin-5-yl, 1-methyl-1H-pyrimidin-2-one-5-yl, and 3,6-dimethoxy-pyridazin-4-yl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 34 of 47

20. (Previously presented) A compound of formula I according to claim 1 comprising one or more of the following:

R1 is methoxy,

R2 is ethoxy, difluoromethoxy or 2,2-difluoroethoxy, and

R3 and R31 are both hydrogen,

R4 is -O-R41, in which

R41 is hydrogen, and

R5 is hydrogen, Har is substituted by R6 and R7, and is pyridinyl, and

Har is optionally substituted by R6 and/or R7, and is pyrimidinyl or pyridazinyl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

21. (Previously presented) A compound of formula I according to claim 1 comprising one or more of the following:

R1 is methoxy,

R2 is ethoxy, difluoromethoxy or 2,2-difluoroethoxy, and

R3 and R31 are both hydrogen,

R4 is -O-R41, in which

R41 is hydrogen, and

R5 is hydrogen, and

Har is either N-methyl-pyrid-2-onyl or N-methyl-pyrimid-2-onyl,

or imidazol-1-yl-pyridinyl or pyrazol-1-yl-pyridinyl,

or methylthio-pyrimidinyl, methoxy-pyrimidinyl, dimethylamino-pyrimidinyl or

pyrimidinyl,

or

Har is substituted by R6 and R7, and is pyridinyl, in which

R6 is methoxy or ethoxy, and

R7 is methoxy or ethoxy,

or

Har is substituted by R6 and R7, and is pyrimidinyl or pyridazinyl, in which

R6 is methoxy, ethoxy or dimethylamino, and

R7 is methoxy or ethoxy,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

22. (Currently amended) A compound of formula I according to claim 1 which is selected from the group consisting of

(2RS,4aRS,10bRS)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(3-methyl-3H-imidazol-4-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(2-pyridin-3-yl-thiazol-4-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-6-isoxazol-5-yl-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8,9-Dimethoxy-6-pyridin-4-yl-1,2,3,4,4a,10b-hexahydro-

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 36 of 47

phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8,9-Dimethoxy-6-pyridin-3-yl-1,2,3,4,4a,10b-hexahydro-

phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8,9-Dimethoxy-6-(6-morpholin-4-yl-pyridin-3-yl)-1,2,3,4,4a,10b-

hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,2,5]oxadiazol-5-yl-9-(1,1-difluoro-methoxy)-8-methoxy-

1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,2,5]oxadiazol-5-yl-9-(2,2-difluoro-ethoxy)-8-methoxy-

1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,2,5]oxadiazol-5-yl-8-(1,1-difluoro-methoxy)-9-methoxy-

1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-9-ethoxy-8-methoxy-

1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,3]dioxol-5-yl-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-

hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzothiazol-6-yl-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-

phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8,9-Dimethoxy-6-quinolin-6-yl-1,2,3,4,4a,10b-hexahydro-

phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-8,9-dimethoxy-

1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,2,5]oxadiazol-5-yl-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 37 of 47

hexahydro-phenanthridin-2-ol,
(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(1-methyl-1H-imidazol-2-yl)-1,2,3,4,4a,10b-
hexahydro-phenanthridin-2-ol,
5-((2RS,4aRS,10bRS)-9-Ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-
phenanthridin-6-yl)-pyridine-2-carboxylic acid methyl ester,
(2RS,4aRS,10bRS)-9-(2,2-Difluoro-ethoxy)-6-(2,6-dimethoxy-pyridin-3-yl)-8-methoxy-
1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,
(2RS,4aRS,10bRS)-9-(2,2-Difluoro-ethoxy)-8-methoxy-6-(2-methoxy-pyridin-3-yl)-
1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,
(2RS,4aRS,10bRS)-9-(2,2-Difluoro-ethoxy)-8-methoxy-6-(6-morpholin-4-yl-pyridin-3-yl)-
1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,
(2RS,4aRS,10bRS)-9-(2,2-Difluoro-ethoxy)-8-methoxy-6-pyridin-3-yl-1,2,3,4,4a,10b-
hexahydro-phenanthridin-2-ol,
(2RS,4aRS,10bRS)-9-(2,2-Difluoro-ethoxy)-6-(2,6-dimethoxy-pyrimidin-4-yl)-8-methoxy-
1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,
(2RS,4aRS,10bRS)-8-(2,2-Difluoro-ethoxy)-6-(2,6-dimethoxy-pyridin-3-yl)-9-methoxy-
1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,
(2RS,4aRS,10bRS)-6-(2,6-Dimethoxy-pyridin-3-yl)-8,9-dimethoxy-1,2,3,4,4a,10b-
hexahydro-phenanthridin-2-ol,
(2RS,4aRS,10bRS)-6-(2,6-Dimethoxy-pyridin-4-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-
hexahydro-phenanthridin-2-ol,
(2RS,4aRS,10bRS)-6-(3-Chloro-2,6-dimethoxy-pyridin-4-yl)-9-(2,2-difluoro-ethoxy)-8-

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 38 of 47

methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,
(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-pyrimidin-5-yl-1,2,3,4,4a,10b-hexahydro-
phenanthridin-2-ol,
(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(6-pyrazol-1-yl-pyridin-3-yl)-1,2,3,4,4a,10b-
hexahydro-phenanthridin-2-ol,
(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-
1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,
6-((2R,4aR,10bR)-9-Ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-
phenanthridin-6-yl)-nicotinic acid methyl ester,
(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(2-methoxy-pyrimidin-5-yl)-1,2,3,4,4a,10b-
hexahydro-phenanthridin-2-ol,
(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(2,4,6-trimethoxy-pyrimidin-5-yl)-1,2,3,4,4a,10b-
hexahydro-phenanthridin-2-ol,
(2R,4aR,10bR)-6-(2,4-Dimethoxy-pyrimidin-5-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-
hexahydro-phenanthridin-2-ol,
(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(5-methyl-pyrazin-2-yl)-1,2,3,4,4a,10b-
hexahydro-phenanthridin-2-ol,
(2R,4aR,10bR)-6-(2,6-Dimethoxy-pyrimidin-4-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-
hexahydro-phenanthridin-2-ol,
(2R,4aR,10bR)-9-Ethoxy-6-(6-imidazol-1-yl-pyridin-3-yl)-8-methoxy-1,2,3,4,4a,10b-
hexahydro-phenanthridin-2-ol,
(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-pyrazin-2-yl-1,2,3,4,4a,10b-hexahydro-

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 39 of 47

phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(1-methyl-1H-benzotriazol-5-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(4-methoxy-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2S,4aS,10bS)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(3SR,4aRS,10bRS)-8,9-Dimethoxy-6-pyridin-3-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-3-ol,

(2R,4aR,10bR)-6-(4-Chloro-2,6-dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(2-methylsulfanyl-pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(4-methyl-2-methylsulfanyl-pyrimidin-5-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(5-Chloro-2-methylsulfanyl-pyrimidin-4-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(2-methoxy-pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 40 of 47

5-((2R,4aR,10bR)-9-Ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-1-methyl-1H-pyridin-2-one,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(6-methoxy-pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(4-Chloro-2-dimethylamino-pyrimidin-5-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(2-Dimethylamino-4-methoxy-pyrimidin-5-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(4,6-Diethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(4,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(2-Dimethylamino-pyrimidin-5-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(5,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-6-(5-ethoxy-6-methoxy-pyridin-3-yl)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(2-methylsulfanyl-pyrimidin-5-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

5-((2R,4aR,10bR)-9-Ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-1-methyl-1H-pyrimidin-2-one,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 41 of 47

(2R,4aR,10bR)-9-Ethoxy-6-(6-hydroxy-pyridin-3-yl)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(3,6-Dimethoxy-pyridazin-4-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(4,6-Dimethoxy-pyrimidin-5-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-pyridin-4-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-pyridin-3-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(6-morpholin-4-yl-pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-(1,1-Difluoro-methoxy)-6-(2,6-dimethoxy-pyridin-3-yl)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8-(1,1-Difluoro-methoxy)-6-(2,6-dimethoxy-pyridin-3-yl)-9-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,2,5]oxadiazol-5-yl-8-(1,1-difluoro-methoxy)-9-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(2,6-Dimethoxy-pyrimidin-4-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(5-Chloro-2,6-bis-dimethylamino-pyrimidin-4-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 42 of 47

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-pyrimidin-5-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-pyrazin-2-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(5-Chloro-4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(6-pyrazol-1-yl-pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-6-(6-imidazol-1-yl-pyridin-3-yl)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,2,3]thiadiazol-5-yl-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-[6-(2-pyrrolidin-1-yl-ethyl)-pyridin-3-yl]-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(2-methoxy-pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(1-methyl-1H-benzotriazol-5-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-quinoxalin-5-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(3-Chloro-2,6-dimethoxy-pyridin-4-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

MAIL STOP AMENDMENT

Serial No. 10/590,803

Page 43 of 47

(2RS,4aRS,10bRS)-8-(1,1-Difluoro-methoxy)-9-methoxy-6-pyridin-3-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8-(1,1-Difluoro-methoxy)-9-methoxy-6-(6-morpholin-4-yl-pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

5-((2R,4aR,10bR)-9-Ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-pyridine-2-carboxylic acid,

(2S,4aS,10bS)-6-(2,6-Dimethoxy-pyridin-3-yl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,


~~(2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-8,9-dimethoxy-1,2,3,4,4^a,10b-hexahydro-phenanthridin-2-ol,~~

(2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(3SR,4aRS,10bRS)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-3-ol,


and the salts, enantiomers, N-oxides, salts of the N-oxides and enantiomers thereof.

23. (Previously presented) A compound of formula I according to claim 1, which has with respect to the positions 4a and 10b the configuration shown in formula I*:



or a salt, N-oxide or salt of an N-oxide thereof.

24. (Previously presented) A compound of formula I according to claim 1, which has with respect to the positions 2, 4a and 10b the configuration shown in formula Ia*****, or, which has with respect to the positions 3, 4a and 10b the configuration shown in formula Ib*****:



or a salt, N-oxide or salt of an N-oxide thereof.

25. – 31. (Canceled)